The New Role(s) of CDMOs In Biopharmaceutical Development

The CDMO landscape is evolving constantly. Our CSO and Managing Director Andreas Schaaf recently joined an insightful online webinar to discuss “The New Role(s) of CDMOs in Biopharmaceutical Development” organized by IMAPAC.

Together with his fellow panelists Tyler Goodwin, Ph.D. of Tune Therapeutics, Dr. Pavan Beleyur Narayanaswamy of AATec Medical, Dainius Guzauskas of InflaRx N.V., and Jan F Talts of Amniotics AB, Andreas took a deep dive into ways to unlock unique product opportunities by applying transformative production technologies. Transformative production technologies – such as Eleva’s moss-based expression platform – unlock effective manufacture of previously uncharted biologics at scale.

This and other topics featured in the webcast will be further intensified at the upcoming “Biologics Manufacturing Germany” Conference from October 22–23 at the Marriott Munich Airport, Germany. Feel free to reach out, to meet Andreas on-site.

Back to